ALNY - Alnylam Pharmaceuticals Non-GAAP EPS of -$1.06 beats by $0.37 revenue of $319.29M beats by $6.76M
2023-05-04 08:04:24 ET
- Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q1 Non-GAAP EPS of -$1.06 beats by $0.37 .
- Revenue of $319.29M (+49.7% Y/Y) beats by $6.76M .
- Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Million to $1,285
For further details see:
Alnylam Pharmaceuticals Non-GAAP EPS of -$1.06 beats by $0.37, revenue of $319.29M beats by $6.76M